Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
Bristol-Myers Squibb Community
NYSE:BMY Community
4
Narratives
written by author
0
Comments
on narratives written by author
319
Fair Values set
on narratives written by author
Create a narrative
Bristol-Myers Squibb
Latest
Undervalued
Overvalued
Community Investing Ideas
Bristol-Myers Squibb
AN
AnalystConsensusTarget
Consensus Narrative from 22 Analysts
Opdivo Pipeline Readouts And Cost Savings Will Secure Future Potential
Key Takeaways Expansion in market acceptance and international approvals of key products drives robust growth, bolstered by promising new indications and oncology programs. Strategic cost efficiency and robust capital allocation efforts enhance financial performance and support sustained earnings growth through 2025.
View narrative
US$57.20
FV
18.1% undervalued
intrinsic discount
-4.24%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
175
users have followed this narrative
4 days ago
author updated this narrative
Bristol-Myers Squibb
EV
Evangelos
Community Contributor
Bristol Myers Squibb (BMY): Undervalued Opportunity or Value Trap? A Deep Dive into 2024 Earnings and Fair Value
Fourth Quarter 2024 Highlights: Total Revenues: $12.3 billion, an 8% increase from the same period in 2023. GAAP Earnings Per Share (EPS): $0.04, a significant decrease from $0.87 in Q4 2023.
View narrative
US$65.00
FV
27.9% undervalued
intrinsic discount
2.43%
Revenue growth p.a.
Set Fair Value
3
users have liked this narrative
0
users have commented on this narrative
10
users have followed this narrative
4 months ago
author updated this narrative
Bristol-Myers Squibb
AN
AnalystLowTarget
Consensus Narrative from 22 Analysts
Clinical Setbacks And Breyanzi Wins Will Reshape Future Outlook
Key Takeaways Disappointing study results and a legacy portfolio decline could hinder revenue growth and investor confidence in Bristol-Myers Squibb's product diversification. Complex global factors and regulatory challenges might elevate costs, impacting net margins and earnings, while cost-saving plans face execution risks.
View narrative
US$41.20
FV
13.7% overvalued
intrinsic discount
-5.34%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
4 days ago
author updated this narrative
Bristol-Myers Squibb
AN
AnalystHighTarget
Consensus Narrative from 22 Analysts
Late Stage Pipelines And Aging Demographics Will Expand Treatment Markets
Key Takeaways Expanding late-stage pipeline, recent product launches, and global growth initiatives are driving long-term revenue opportunities, especially in emerging markets and chronic disease segments. Strategic investment in innovation, cost optimization, and business development is enhancing profitability, reducing risk, and supporting sustained shareholder returns.
View narrative
US$68.00
FV
31.1% undervalued
intrinsic discount
-2.21%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
4 days ago
author updated this narrative
Your Valuation for
BMY
BMY
Bristol-Myers Squibb
Your Fair Value
US$
Current Price
US$46.86
80.6% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-6b
48b
2015
2018
2021
2024
2025
2027
2030
Revenue US$36.6b
Earnings US$4.2b
Advanced
Set Fair Value